STERIS’ (TSE:STE – Free Report) – Investment analysts at Raymond James lowered their FY2026 earnings per share estimates for shares of STERIS’ in a research report issued on Wednesday, April 9th. Raymond James analyst M. Barth now expects that the company will earn $0.48 per share for the year, down from their previous estimate of $0.72. Raymond James has a “Hold” rating on the stock.
A number of other brokerages have also recently weighed in on STE. Cormark raised shares of STERIS’ to a “moderate buy” rating in a research note on Monday, January 6th. Atb Cap Markets raised STERIS’ to a “strong-buy” rating in a research report on Sunday, December 22nd.
STERIS’ Stock Performance
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Featured Articles
- Five stocks we like better than STERIS’
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Is McDonald’s Stock Serving a Value Meal to Investors?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Walgreens Comeback? Private Equity Circling for a Buyout
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Coca-Cola Stock Looks Refreshing After the Relief Rally
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
